Cargando…

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells

The chromosomal translocation t(14;18) in follicular lymphoma (FL) is a primary oncogenic event resulting in BCL-2 over-expression. This study investigates activity of the BH3 mimetic venetoclax (ABT-199), which targets BCL-2, and mechanisms of acquired resistance in FL. The sensitivity of FL cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodo, Juraj, Zhao, Xiaoxian, Durkin, Lisa, Souers, Andrew J., Phillips, Darren C., Smith, Mitchell R., Hsi, Eric D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342530/ https://www.ncbi.nlm.nih.gov/pubmed/27661108 http://dx.doi.org/10.18632/oncotarget.12132

Ejemplares similares

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

The Premalignant Ancestor Cell of t(14;18)(+) Lymphoma
por: Brisou, Gabriel, et al.
Publicado: (2021)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
por: Salaverria, Itziar, et al.
Publicado: (2023)

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells
por: Valdez, Benigno C., et al.
Publicado: (2022)

Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma
por: O'Neill, John Patrick, et al.
Publicado: (2018)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Relapse of follicular lymphoma arising from a non‐t(14;18) clone
por: Otsuka, Yasuyuki, et al.
Publicado: (2020)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Translocation t(14;18) in B cell lymphomas as a cause for defective immunoglobulin production
Publicado: (1989)

Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas
Publicado: (1986)

Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
por: Shi, Yuanfei, et al.
Publicado: (2022)

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.
por: Pezzella, F., et al.
Publicado: (1992)

High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren's syndrome patients
Publicado: (1991)

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
por: Abbott, David R., et al.
Publicado: (2009)

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
por: Leich, Ellen, et al.
Publicado: (2021)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma
por: Nambiar, Mridula, et al.
Publicado: (2011)

t(14;18)-negative Follicular Lymphomas Are Associated with a High Frequency of BCL6 Rearrangement at the Alternative Breakpoint Region
por: Gu, Keni, et al.
Publicado: (2009)

Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups
por: Zhang, Fen, et al.
Publicado: (2013)

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018)

Occupational exposure to pesticides and occurrence of the chromosomal translocation t(14;18) among farmers in Jordan
por: Qaqish, Bara’a M., et al.
Publicado: (2016)

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas
por: Soubeyran, P, et al.
Publicado: (1999)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

Molecular Evaluation of t(14;18)(bcl-2/IgH) Translocation in Follicular Lymphoma at Diagnosis Using Paraffin-Embedded Tissue Sections
por: Selvi, Nur, et al.
Publicado: (2012)

Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion
por: Sheng, Iris Y., et al.
Publicado: (2017)

Presence of t(14;18) translocation in healthy individuals varies according to ethnic background in the Brazilian population
por: Levy, D., et al.
Publicado: (2017)

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

Lymphomas with testicular localisation show a consistent BCL-2 expression without a translocation (14;18): a molecular and immunohistochemical study.
por: Lambrechts, A. C., et al.
Publicado: (1995)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality
por: Elyamany, Ghaleb, et al.
Publicado: (2014)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
por: Haddad, Fady Gh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8007hofojpgpj7nsb9h338irn4